Crown Marketing to Launch Nutraceuticals Products

CHAPEL HILL, NC--(Marketwired - Apr 24, 2013) - Crown Marketing ( OTCQB : CWNM ) is pleased to announce that its subsidiary, Crown Nutraceuticals, Inc. will launch their first nutraceuticals and supplements product line anticipating sales to begin within the next thirty days. 

Crown's initial entrants into the market will be two popular diet products widely recognized to be safe and effective treatments for weight loss: Raspberry Ketones and Green Coffee Bean Extract. Although these products will not, initially, be utilizing Crown's patented Controlled Delivery Technology, Crown expects to roll-out their proprietary delivery technology in subsequent offerings.

About Crown Nutraceuticals:

Crown Nutraceuticals is engaged in the development, manufacturing and marketing of popular nutraceuticals and supplements.

The Global Nutraceuticals Product market is massive -- reaching over 142.1 billion in 2011 and is expected to reach 204.8 billion by 2017, growing at a CAGR of 6.3% from 2012 to 2017. Asia Pacific (including Japan) is expected to have the second largest market share after North America by 2017.

About Crown Marketing:

Crown Marketing's Controlled Drug Delivery Technology (CDDT) holds patents for a novel controlled-release technology, harnessing the principles of chaos theory along with precise mathematical formulas for precise and programmable diffusion delivery.

The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels. 

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at: www.crowncddt.com

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.